HomeAI · summaries
Storia in 9 fonti
AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News
<p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti, un'operazione che rafforza il portafoglio di farmaci immunologici e...
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
valor.globo.com
FT: AbbVie está perto de comprar Apogee Therapeutics por US$ 11 bi
Negócio chega em meio a aumento de compras de companhias de biotecnologia e ao interesse das grandes farmacêuticas para reforçar desenvolvimento de remédios
- ·
biopharmadive.com
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…
- ·
endpoints.news
AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
- ·
statnews.com
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
- ·
AbbVie acerta aquisição da Apogee Therapeutics por US$ 10,9 bilhões em dinheiro
Acordo que reforça o portfólio de imunologia e inflamação da farmacêutica
- ·
wiwo.de
Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar
AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.
- ·
benzinga.com
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
- ·
investors.com
AbbVie Goes On The Offensive With $10.9 Billion Takeover
The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.
- ·
expansion.com
AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares
Seg�n los t�rminos del acuerdo, AbbVie pagar� un prima cercana al 50% respecto al cierre en Bolsa de Apogee Therapeutics el pasado jueves, ya que el viernes no hubo sesi�n en...
- ·
milanofinanza.it
AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News
<p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti, un'operazione che rafforza il portafoglio di farmaci…
- ·
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.